アジア太平洋のシングルセルマルチオミクス市場：分析と予測（2023年～2033年）

アジア太平洋地域のシングルセルマルチオミクスの市場規模は、2023年の3億米ドルから2033年には18億5,000万米ドルに達し、予測期間の2023年～2033年年に20.00%のCAGRで拡大すると予測されています。

この市場は、大規模ゲノム研究におけるシングルセルRNAシーケンシング（Sc-RNA）の利用の増加、病気のスクリーニングや診断にシングルセルマルチオミクスアプローチを採用する個別化医療への移行、医薬品開発におけるシングルセルマルチオミクスの導入の増加など、さまざまな要因によって成長しています。

アジア太平洋（APAC）のシングルセルマルチオミクス市場は、いくつかの重要な要因によって著しい成長を遂げています。これには、地域全体でゲノミクス研究におけるシングルセルマルチオミクス技術の採用が増加していることが含まれます。個別化医療が注目されるにつれ、病気のスクリーニングや診断にシングルセルマルチオミクスアプローチを活用する方向へのシフトが進んでいます。さらに、APAC地域では、医薬品開発プロセスにおけるシングルセルマルチオミクスの応用が増加傾向にあります。ゲノム研究を支援する政府のイニシアチブとヘルスケアインフラの進歩が、さらに市場成長に寄与しています。膨大な人口と精密医療への注目の高まりにより、APACのシングルセルマルチオミクス市場は、研究機関、製薬会社、ヘルスケアプロバイダーにとって、疾患の理解を深め、個々の患者に合わせた標的療法を開発するための有望な機会を提示しています。

当レポートでは、アジア太平洋のシングルセルマルチオミクス市場について調査し、市場の概要とともに、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

第1章 市場

• 市場の見通し
• 市場概要
• 業界の展望
• COVID-19の影響
• ビジネスダイナミクス

第2章 シングルセルマルチオミクス市場（地域別）

• アジア太平洋

第3章 市場-競合ベンチマーキングと企業プロファイル

• 競合ベンチマーキング
  • 主要な戦略と展開
  • 市場シェア分析
  • 成長シェア分析
  • 企業のビジュアルグラフィックス
  • マルチオミクスエコシステムの活躍企業
• 企業プロファイル
  • BGI Group
  • Shilps Sciences
  • Takara Bio Inc.

List of Figures

• Figure 1: An Overview of Single-Cell Multi-Omics Sequencing Technologies
• Figure 2: Single-Cell Multi-Omics Market, Impact Analysis
• Figure 3: Asia-Pacific Single-Cell Multi-Omics Market (by Application), % Share, 2022 and 2033
• Figure 4: Single-Cell Multi-Omics Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: Single-Cell Multi-Omics Market, Patent Analysis (by Country), January 2018- March 2023
• Figure 9: Single-Cell Multi-Omics Market, Patent Analysis (by Year), January 2018-December2022
• Figure 10: Single-Cell Multi-Omics Market, Key Trends, Market Shift, 2022-2033
• Figure 11: Single-Cell Multi-Omics Market, Impact Analysis
• Figure 12: Data for Rare Diseases, 2020
• Figure 13: Companies Using Multi-Omics Approach in Research and Development of Drugs and Vaccines
• Figure 14: Advantages of Multi-Omics in Drug Discovery and Development
• Figure 15: Cost of Single Cell Sequencing (by Company)
• Figure 16: Some of the Advancements in Single-Cell Metabolomics
• Figure 17: Single-Cell Multi-Omics Market Share (by Region)
• Figure 18: Asia-Pacific Single-Cell Multi-Omics Market Incremental Revenue Opportunity (by Country), $Million, 2023-2033
• Figure 19: Asia-Pacific Single-Cell Multi-Omics Market, $Billion, 2022-2033
• Figure 20: Asia-Pacific Single-Cell Multi-Omics Market (by Country), % Share, 2022 and 2033
• Figure 21: China Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 22: Japan Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 23: India Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 24: Singapore Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 25: Australia Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 26: Rest-of-Asia-Pacific Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 27: Single-Cell Multi-Omics Market, Number of Key Developments and Strategies, January 2018-March 2023
• Figure 28: Funding Activities, January 2018-March 2023
• Figure 29: New Offerings, January 2018-March 2023
• Figure 30: Mergers and Acquisitions, January 2018-March 2023
• Figure 31: Partnership, Collaboration, and Business expansion, January 2018-March 2023
• Figure 32: Single-Cell Multi-Omics Market, Company Revenue Share Analysis, $Billion, 2022
• Figure 33: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Application), 2023-2033
• Figure 34: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Omics Type), 2023-2033
• Figure 35: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Product Type), 2023-2033
• Figure 36: Single Cell Multi Omics Market, Visual Graphics of the Companies
• Figure 37: BGI Genomics.: Product Portfolio
• Figure 38: BGI Genomics: Overall Financials, $Million, 2020-2022
• Figure 39: Shilps Sciences: Product Portfolio
• Figure 40: Takara Bio Inc.: Product Portfolio
• Figure 41: Takara Bio Inc.: Overall Financials, $Million, 2020-2022
• Figure 42: Takara Bio Inc.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 43: Takara Bio Inc.: Net Revenue (by Region), $Million, 2020-2022
• Figure 44: Takara Bio Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: Single-Cell Multi-Omics Market, Key Developments Analysis, January 2018-March 2023
• Table 2: Key Questions Answered in the Report
• Table 3: Single-Cell Multi-Omics Market: Global Regulatory Organization
• Table 4: Single-Cell Multi-Omics Market, Product Benchmarking
• Table 5: Single-Cell Multi-Omics Market, Ongoing Clinical Trials
• Table 6: Single-Cell Multi-Omics Platforms Used in the Diagnosis of Disease
• Table 7: Recent Collaborations between Technology Providers and Life Sciences Companies
• Table 8: Asia-Pacific Single-Cell Multi-Omics Market Dynamics, Impact Analysis
• Table 9: Multi-Omics Ecosystem Active Players

The Asia-Pacific Single-Cell Multi Omics Market Expected to Reach $1.85 Billion by 2033

Introduction to Asia-Pacific Single-Cell Multi-Omics Market

The Asia-Pacific single-cell multi-omics market is projected to reach $1.85 billion by 2033 from $0.30 billion in 2023, growing at a CAGR of 20.00% during the forecast period 2023-2033. The market is growing owing to various factors, such as the rising use of single-cell RNA sequencing (Sc-RNA) in large-scale genomics studies, a transition toward personalized medicine employing the single-cell multi-omics approach for disease screening and diagnostics, and increased uptake of single-cell multi-omics in drug development.

Market Introduction

The Asia-Pacific (APAC) single-cell multi-omics market is experiencing notable growth, driven by several key factors. This includes the increasing adoption of single-cell multi-omics technologies in genomics studies across the region. As personalized medicine gains prominence, there's a growing shift towards utilizing single-cell multi-omics approaches for disease screening and diagnostics. Moreover, the APAC region is witnessing a rising trend in the application of single-cell multi-omics in drug development processes. Government initiatives supporting genomic research and advancements in healthcare infrastructure further contribute to market growth. With a vast population and increasing focus on precision medicine, the APAC single-cell multi-omics market presents promising opportunities for research institutions, pharmaceutical companies, and healthcare providers to enhance understanding of diseases and develop targeted therapies tailored to individual patients.

Market Segmentation:

Segmentation 1: by Country

• China
• Japan
• India
• Australia
• Singapore
• Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: The APAC single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.

Competitive Strategy: The APAC single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

• BGI Group
• Shilps Sciences
• Takara Bio Inc.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
• 1.2 Market Overview
  • 1.2.1 Key Findings
  • 1.2.2 Current Market Scenario
    • 1.2.2.1 For Researchers
    • 1.2.2.2 For Diagnostics
• 1.3 Industry Outlook
  • 1.3.1 Regulatory Framework
  • 1.3.2 Patent Analysis
    • 1.3.2.1 Awaited Technological Developments
    • 1.3.2.2 Patent Filing Trend (by Country)
    • 1.3.2.3 Patent Filing Trend (by Year)
  • 1.3.3 Key Trends
    • 1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
    • 1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
    • 1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
  • 1.3.4 Opportunity Assessment
  • 1.3.5 Product Benchmarking
  • 1.3.6 Clinical Trials
• 1.4 COVID-19 Impact
  • 1.4.1 Pre-COVID-19
  • 1.4.2 During COVID-19
  • 1.4.3 Post COVID-19
• 1.5 Business Dynamics
  • 1.5.1 Impact Analysis
  • 1.5.2 Business Drivers
    • 1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
    • 1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
    • 1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
    • 1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
  • 1.5.3 Business Restraints
    • 1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
    • 1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
  • 1.5.4 Business Opportunities
    • 1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
    • 1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations

2 Single-Cell Multi-Omics Market (by Region)

• 2.1 Asia-Pacific
  • 2.1.1 Key Findings and Opportunity Assessment
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Sizing and Forecast Analysis
    • 2.1.3.1 Asia-Pacific Single-Cell Multi-Omics Market (by Country)
      • 2.1.3.1.1 China
      • 2.1.3.1.2 Japan
      • 2.1.3.1.3 India
      • 2.1.3.1.4 Singapore
      • 2.1.3.1.5 Australia
      • 2.1.3.1.6 Rest-of-Asia-Pacific

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 New Offerings
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 Partnership, Collaboration, and Business Expansion
  • 3.1.2 Market Share Analysis
  • 3.1.3 Growth Share Analysis
    • 3.1.3.1 By Application
    • 3.1.3.2 By Omics Type
    • 3.1.3.3 By Product Type
  • 3.1.4 Visual Graphics of the Companies
  • 3.1.5 Multi-Omics Ecosystem Active Players
• 3.2 Company Profiles
  • 3.2.1 BGI Group
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Role of BGI Group in the Single-Cell Multi-Omics Market
    • 3.2.1.3 Financials
    • 3.2.1.4 Analyst Perspective
  • 3.2.2 Shilps Sciences
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Role of Shilps Sciences in the Single-Cell Multi-Omics Market
    • 3.2.2.3 Analyst Perspective
  • 3.2.3 Takara Bio Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Role of Takara Bio Inc. in the Single-Cell Multi-Omics Market
    • 3.2.3.3 Financials
    • 3.2.3.4 Analyst Perspective